Clinical application of Chemiluminescence Microparticle Immunoassay for SARS-CoV-2 infection diagnosis
Detection Principle
ImmunoAssay-Others
Target
Chemiluminescence Microparticle Immunoassay (CMIA) IgM and total Antibodies
Testing Method Category
Other
Testing Method
Xiamen InnoDx Biotech Co., Ltd., China (Xiamen, China).
Testing Method - Additional Info
CMIA has high sensitivity and specificity for the detection of serum samples, especially the durations from symptom onset to this serological test was more than 7 days
Reported Performance
specificity: 99.3% (IgM), 98.9% (TotalAb )
Sample Size
206 patients
Peer-reviewed
yes
The database contains available information from scientific literature that is being updated periodically. Please note that the provided information (as retrieved from analysed papers) is provided only for devices commercially available with CE-IVD mark. Acknowledgements